Pharmafile Logo
Pharmafocus logo
Advanced Search

Glivec

Showing 7 posts of 22 posts found.

Novartis ends phase III trial of Tasigna

April 12, 2011
GIST, Glivec, Novartis, Tasigna

Novartis has stopped a late stage study of Tasigna for certain types of stomach cancers after it failed to show …

News

Trial hitch for Pfizer’s leukaemia drug submission plans

December 7, 2010
Research and Development, Sales and Marketing CML, Gleevec, Glivec, Pfizer, bosutinib, chronic myeloid leukaemia

Pfizer is pressing ahead with plans to submit bosutinib for European approval despite the chronic myeloid leukaemia drug missing its …

News

NICE recommends Herceptin for gastric cancer, blocks high dose Glivec

November 24, 2010
Sales and Marketing Cancer, GIST, Glivec, HER2, Herceptin, NICE, gastric cancer

NICE has recommended Roche’s cancer drug Herceptin for patients with HER2 metastatic gastric cancer. NICE was initially minded not to …

News
Glivec pack

Higher dose of Glivec not cost effective, says NICE

June 29, 2010
Sales and Marketing Glivec, NICE, gastric cancer

 

News

NICE rejects Glivec as adjuvant therapy

June 24, 2010
Sales and Marketing Glivec, NICE, Novartis

NICE has rejected the use of Novartis’ Glivec as an adjuvant treatment for people who have had a gastrointestinal stromal …

News

Tasigna more effective than Glivec, says Novartis

June 21, 2010
Research and Development, Sales and Marketing Glivec, Novartis, Tasigna, leukaemia

Novartis has gained US approval for Tasigna to be used as a front line treatment for chronic myeloid leukaemia. The …

News
Glivec pack

NICE seeks compromise over Glivec approval

March 24, 2010
Sales and Marketing Glivec, NICE, Novartis

NICE says it is unlikely to approve the use of Glivec against gastrointestinal stromal tumours (GISTs) after surgery, but is …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026